101 Real-world Analysis of the Impact of Pemetrexed in First-Line Maintenance (1LM) with Immunotherapy (IO) for Non-Squamous (NSQ) Advanced/metastatic Non-Small Cell Lung Cancer (a/mnsclc) Lacking Targetable Mutations, Prior to and During the COVID-19 Pandemic